Oslo, Norway-headquartered Navamedic has completed its previously announced acquisition of dne pharma’s business for Nkr225m ($22m).
This acquisition comprises dne pharma’s entire business: its product portfolio, key personnel, all vital contracts, intellectual property, distribution agreements and licenses.
They will be integrated into the existing commercial platform of Navamedic, aiming to facilitate rapid market access and expansion within Nordic and selected markets in Europe.
The acquired products from dne pharma include Ventizolve (intranasal naloxone spray), Levopidon (levomethadone) and Metadon Dne (methadone), which is used for opioid substitution therapy.
The initial transaction announced in June 2025 stated a payment of Nkr185m at closing and an additional Nkr40m dependent on future sales volumes.
Navamedic CEO Kathrine Gamborg Andreassen stated: “This acquisition represents a significant step in our strategic expansion into the rapidly growing field of addiction treatment and is well aligned with our long-term growth ambitions.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData鈥淭hanks to the strong collaboration among all parties involved, the transaction was completed smoothly and efficiently. We are pleased that the General Meeting unanimously approved the rights issue yesterday, and we are sincerely grateful for the continued support of Kistefos and the other underwriters.鈥�
To finance the acquisition, Navamedic secured new debt facilities amounting to Nkr110m from Nordea Bank Abp, filial i Norge (Nordea), supplemented by equity raised through a rights issue. A bridge loan provided by Nordea facilitated the prompt completion of the deal ahead of finalising the rights issue proceeds.
In arranging this transaction, Navamedic was assisted by DNB Carnegie, part of DNB Bank, and Thommessen for advisory services.
Both DNB Carnegie and Nordea Corporate Finance continued as managers for the rights issue, with Thommessen continuing its role as legal advisors.
dne pharma CEO Geir Ove Engeset stated: 鈥淲e are very pleased to close this transaction with Navamedic, and we are confident that the Navamedic team will continue to grow the opioid substitution business developed by dne pharma, in particular the Ventizolve products.鈥�
